Blockade of colon cancer metastasis via single and double silencing of PCSK7/PCSK9: enhanced T cells cytotoxicity in mouse and human
Background Immunotherapy approaches based on T cells provided breakthroughs in cancer treatment but could cause many immune-related adverse events, and their efficacy is limited for many cancers with an acquired dysfunction/exhaustion of T cells. The present study presents a novel role in immunity f...
Saved in:
| Main Authors: | Delia Susan-Resiga, Nabil G Seidah, Nathalie Labrecque, Jean-Sebastien Delisle, Leila Jafarzadeh, Chloé Porcheron, Mailys Le Devehat, Anna Roubtsova, Hadi Bayat, Alexandra Evagelidis, Vatsal Sachan, Alexie Fonta Holder, Rachid Essalmani, Gabrielle Boudreau, Annik Prat, Rebecca Cusseddu, Jean-François Côté, Abdel-Majid Khatib |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-06-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/13/6/e011364.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PCSK9-antibodies fail to block PCSK9-induced inflammation in macrophages and cannot recapitulate protective effects of PCSK9-deficiency in experimental myocardial infarction
by: Simon Rauterberg, et al.
Published: (2025-01-01) -
PCSK9 Inhibitors: The Evolving Future
by: Bijay Mukesh Jeswani, et al.
Published: (2024-11-01) -
PCSK9 in T-cell function and the immune response
by: Yuying Wang, et al.
Published: (2024-12-01) -
PCSK7 levels in women with and without PCOS
by: Stephen L. Atkin, et al.
Published: (2024-12-01) -
Analysis of The Use of PCSK9 Inhibitors in Clinical Practice
by: S. Yu. Volkova, et al.
Published: (2023-03-01)